Ascendis Pharma A/S (ASND)

Ascendis Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	392.16	444.77	446.27	584.52	598.11
Short-Term Investments	7.28	290.69	235.8	134.28	0
Cash & Cash Equivalents	399.44	735.46	682.06	718.8	598.11
Cash Growth	-45.69%	7.83%	-5.11%	20.18%	115.25%
Receivables	57.1	26.66	24.1	8.72	6.88
Inventory	208.93	130.67	75.41	0	0
Other Current Assets	37.25	30.68	24.32	12.62	6.19
Total Current Assets	702.72	923.47	805.89	740.13	611.17
Property, Plant & Equipment	110.63	129.1	126.05	108.11	45.07
Long-Term Investments	5.69	30.42	145.91	124.46	15.54
Goodwill and Intangibles	4.42	4.83	5.27	5.72	3.5
Other Long-Term Assets	2.13	1.92	1.81	1.38	1.46
Total Long-Term Assets	122.87	166.27	279.04	239.66	65.57
Total Assets	825.59	1,090	1,085	979.79	676.73
Accounts Payable	94.57	101.03	59.42	21.9	27.77
Deferred Revenue	7.13	14.21	5.57	0.36	0.86
Current Debt	0	25.42	7	6.86	5.9
Other Current Liabilities	634.81	30.61	28.38	23.69	13.47
Total Current Liabilities	736.51	171.27	100.36	52.8	47.99
Long-Term Debt	644.27	482.96	97.97	85.12	30.72
Other Long-Term Liabilities	-409.49	172.16	2.96	3.16	0.91
Total Long-Term Liabilities	234.78	655.12	100.93	88.28	31.63
Total Liabilities	971.28	826.39	201.29	141.08	79.62
Total Debt	644.27	508.38	104.96	91.98	36.62
Debt Growth	26.73%	384.35%	14.12%	151.17%	-
Retained Earnings	-153.45	255.67	875.99	831.49	590.67
Shareholders' Equity	-145.7	263.35	883.64	838.71	597.11
Net Cash / Debt	-244.83	227.08	577.1	626.82	561.49
Net Cash / Debt Growth	-	-60.65%	-7.93%	11.64%	102.07%
Net Cash Per Share	-4.35	4.05	10.54	12.38	12.07
Working Capital	-33.79	752.2	705.53	687.33	563.18
Book Value Per Share	-2.59	4.70	16.13	16.57	12.84

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).